Clinical trials: Hairy Cell Leukemia (HCL), open to volunteers
Hairy Cell Leukemia (HCL)
Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management
This is a national multi-centre, experimental, cross-sectional, non-profit study.
- Trial name
- NCT06774677
- Where
- 3 sites in Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hairy Cell Leukemia
Therapy Optimisation for the Treatment of Hairy Cell Leukemia
The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment.
- Trial name
- NCT02131753
- Testing
- Cladribine s.c. injection, HCL treatment
- Where
- 76 sites in Germany
- Volunteers
- 210 people
- Sponsor
- University of Giessen
Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
This phase I/II trial tests the safety, side effects, and effectiveness of tovorafenib in combination with rituximab in patients with classical hairy cell leukemia (cHCL) that has come back after a period of improvement…
- Conditions
- Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia
- Trial name
- NCT06965114
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Hairy Cell Leukemia
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
Background: Most people with hairy cell leukemia have a BRAF gene mutation. They can be treated with BRAF inhibitors, drugs that target this mutation.
- Trial name
- NCT04322383
- Testing
- binimetinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL)
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Background: Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samples from leukemia patients and healthy volunteers.
- Conditions
- Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL)
- Trial name
- NCT01087333
- Where
- United States
- Volunteers
- 1,263 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Hairy Cell Leukemia
Assessment of Disease Burden in Hairy Cell Leukemia
Drug-free, single-center, prospective observational pilot study in hairy Cell Leukemia patients
- Trial name
- BRAF (NCT06781515)
- Testing
- Peripheral and BM blood sample
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Follicular Lymphoma, Mantle Cell Lymphoma
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas.
- Conditions
- Follicular Lymphoma, Mantle Cell Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma
- Trial name
- NCT06340737
- Testing
- CD22CART Infusion
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Stanford University
Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma
Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies
Adult patients with chronic lymphocytic leukemia (CLL), splenic marginal-zone lymphoma (SMZL) and hairy cell leukemia (HCL) followed at participating clinical sites will be enrolled and undergo sampling of additional amount of…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma, Hairy Cell Leukemia (HCL)
- Trial name
- IMPACT (NCT07759661)
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- IRCCS San Raffaele
Leukemia, Other
Hairy Cell Leukemia Patient Data Registry
The overall objective is to develop a clinical data registry that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality and improving the quality of life of patients diagnosed or…
- Trial name
- HCL-PDR (NCT02560883)
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 5,000 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hairy Cell Leukemia
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab.
- Trial name
- NCT06561360
- Testing
- Vemurafenib, Obinutuzumab, Cladribine
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hairy Cell Leukemia, Hairy Cell Leukemia Variant
Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant
investigators propose a phase II, open label-nonrandomized, single arm, multicenter study aiming to assess the safety and efficacy with the combination of Rituximab and Zanubrutinib in patients with HAIRY CELL LUKEMIA HCL, or…
- Trial name
- Rituximab+ Zan (NCT07690761)
- Testing
- Zanubrutinib
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Bnai Zion Medical Center
Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia.
- Trial name
- NCT00412594
- Testing
- Cladribine, Laboratory Biomarker Analysis, Rituximab
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory hematologic malignancies, however not all tumors respond or remain in response to CD19 targeted CAR-T cells.
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma
- Trial name
- NCT07679919
- Testing
- LMY-922
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Luminary Therapeutics
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects
Registry of Older Patients With Cancer
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
- Conditions
- Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma
- Trial name
- NCT01137825
- Where
- 7 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT01137643
- Testing
- biologic sample preservation procedure, cytology specimen collection procedure
- Where
- United States
- Volunteers
- 15,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
CLL/SLL, Waldenstrom Macroglobulinemia
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies.
- Conditions
- CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- NCT04775745
- Testing
- LP-168
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Newave Pharmaceutical Inc
Hairy Cell Leukemia (HCL)
Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management
Check whether patients with Hairy Cell Leukemia (HCL) of different status (at diagnosis, in complete remission > 2 years or relapsed requiring therapy) have a 'signature' of altered immunity based on extracellular vesicles (EV)
- Trial name
- NCT06764524
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hairy Cell Leukemia, Hairy Cell Leukemia Variant
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
Background: CAR (Chimeric Antigen Receptor) T cell therapy is a type of cancer treatment in which a person s T cells (a type of immune cell) are changed in a laboratory to recognize and attack cancer cells.
- Trial name
- NCT04815356
- Testing
- CD22CART cell infusion
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)